FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:1699 June 4, 1998 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kawai, A.

To the Editor: In their study of SYT–SSX gene fusion in synovial sarcoma, Kawai et al. (Jan. 15 issue)¹ found a significant relation between the SYT–SSX2 subtype and metastasis-free survival. Adjuvant ifosfamide-based chemotherapy did not appear to be a prognostic factor. The authors conclude "that the survival advantage of the SYT–SSX2 group was not related to treatment with this agent."

Randomized trials have suggested that adjuvant chemotherapy may prolong survival free of distant metastases, but in meta-analyses, only doxorubicin-based adjuvant chemotherapy significantly improves recurrence-free survival in soft-tissue sarcomas.² There are few data about the results with ifosfamide used as a . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.